Biotech market spotlight: Mesoblast
Monday, 09 November, 2009
Regenerative medicine company, Mesoblast (ASX:MSB), has seen some fluctuating share prices over the past week, with it lifting 9.4% since last Monday's open, although it's down 3.3% in today's trading.
On Friday the company announced the latest in a series of successful trials of its stem cell treatments targeted at regenerating and repairing bone and cartilage.
The technology uses mesenchymal precursor cells (MPC), which are a form of adult stem cell that can generate new bone, cartilage, and blood vessels.
Friday's announcement concerned a study involving 18 patients who received bone marrow transplants using umbilical cord blood expanded by MPCs. These patients experienced faster recovery times and lower rates of graft-versus-host disease.
Mesoblast is currently at $1.16, down 4c or 3.33% at the close of trading on Monday evening.
Vaccine for elephant herpesvirus found to be safe
The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...
Pig-to-human liver xenotransplant conducted in a living recipient
The case involved a 71-year-old man with hepatitis B-related cirrhosis and hepatocellular...
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
